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Abstract
Live attenuated oral rotavirus vaccines were tested for proof-of-concept in the early 1980s, the first vaccine (RotaShield, Wyeth) was
introduced in 1998 but was subsequently withdrawn because of association with intussusception, and the two currently licensed vaccine
(Rotarix, GlaxoSmithKline, and RotaTeq, Merck) were introduced in 2006. Before licensure both vaccines were extensively tested
for safety (for intussusception) and efficacy in trials comprising in over 60 000 infants each. Rotarix is a single-strain human rotavirus
vaccine (RV1) and RotaTeq is a combination of five bovine–human reassortant rotaviruses (RV5). Although the composition of the two
vaccines is different, their field effectiveness and, largely, mechanism of action are similar. Both prevent effectively severe rotavirus gas-
troenteritis (RVGE) but are less efficacious against mild RVGE or rotavirus infection. Field effectiveness of these vaccines in Europe and
the USA against severe RVGE has been above 90% and in Latin America around 80%. Trials in Africa have yielded efficacy rates
between 50 and 80%. Rotavirus vaccination has been introduced into the national immunization programmes of about 20 countries in
Latin America, with Brazil and Mexico as leading countries, as well as in the USA, Australia and South Africa. Introduction into other
African countries will start in 2012. In Europe, Belgium, Luxembourg, Austria and Finland and five federal states of Germany have intro-
duced universal rotavirus vaccination. The reasons for the slow progress in Europe include low mortality from RVGE, unfavourable
cost–benefit calculations in some countries, and concerns that still exist over intussusception.
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Introduction
Rotavirus was discovered in 1973 with electron micro-
graphs of intestinal biopsies of children with acute gastroen-
teritis [2] and soon thereafter from stools [3]. Rotavirus
was found to be a major causative agent of acute gastroen-
teritis of childhood, for example, in the USA [4] and Fin-
land [5]. When epidemiological studies were extended to
developing countries it was shown that rotavirus caused a
large proportion of acute diarrhoea around the world, and
was associated with high mortality. The figure that was
commonly cited in the 1980s was 870 000 deaths per year
globally [6]; the current figure is 450 000 [7]. Several fac-
tors, particularly implementation of oral rehydration ther-
apy, have reduced global mortality from diarrhoea, but the
need to prevent rotavirus gastroenteritis (RVGE) by vacci-
nation remains.
The target for rotavirus vaccine development from the
beginning was prevention of global mortality and, in devel-
oped countries, prevention of high morbidity. A live atten-
uated tissue-culture-grown rotavirus administered orally
was a conventional choice for a potential vaccine. It was
thought that an oral vaccine would best mimic the natural
immunity induced by wild-type rotavirus infection in the
intestines. As human rotaviruses could not be grown
in tissue culture until several years later, heterologous
animal rotaviruses were investigated as possible candidate
vaccines.
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2012.03981.x
This is a review on rotavirus vaccine development and
rotavirus vaccination, as seen from my own perspective over
a period of 30 years. For a comprehensive review of all trials
of the currently used vaccine please see a recent Cochrane
Review [1].
Bovine rotavirus—first vaccine
Bovine rotavirus strain NCDV (Nebraska Calf Diarrhea
Virus) had been isolated in 1971, adapted to cell culture,
and could be grown to a high titre of at least 108 median
tissue culture infective dose/mL at passage level 154. The
NCDV strain was renamed RIT4237 after passaging [8].
Human trials were initiated after cross-protection against
human rotaviruses was demonstrated in studies in gnotobi-
otic pigs [9].
A series of human trials were conducted in Finland from
1982 to 1986, starting from phase I studies in adults and
rapidly progressing to efficacy trials in infants. A complete
history of these studies has been presented elsewhere
[10,11]. The key observation was that a single oral dose of
the RIT4237 vaccine given shortly before the winter epi-
demic season of rotavirus effectively (c.90%) prevented
severe rotavirus gastroenteritis although milder break-
through cases happened, resulting in about 50% overall effi-
cacy [12]. The concept that the end point of vaccine
efficacy measurement should be severe gastroenteritis
rather than any RVGE was only gradually accepted, but effi-
cacy against severe RVGE is currently the principal indica-
tor of rotavirus vaccine efficacy.
The definition of ‘severe’ RVGE, however, is not straight-
forward. In the rotavirus vaccine trials in Finland a numerical
score of 1–20 points was developed to assess severity of
RVGE [13]. This scoring system, dubbed a ‘Vesikari score’,
has most often been applied to measure efficacy of rotavirus
vaccines in clinical trials. An example is shown in Fig. 1,
which depicts the distribution of severity of RVGE in patients
given vaccine or placebo, respectively. Although there is no
clear distinction between ‘severe’ and less severe or mild, a
score ‡11/20 has often been used to indicate severe RVGE.
Many other primary observations were made in the early
studies of bovine rotavirus vaccine RIT4237 in Finland
(Table 1). These include requirement of buffering against
stomach acidity and lack of suppression of uptake by breast
milk or feeding. Studies in Italy and Yugoslavia, where oral
poliovirus vaccine was in use, showed interference between
the poliovirus vaccine and the oral rotavirus vaccine. These




Rhesus rotavirus (RRV) was introduced as an alternative (to
bovine) heterologous rotavirus vaccine candidate. The advan-
tage of RRV was its more efficient multiplication in human
intestines and greater immunogenicity. The downside, how-
FIG. 1 Distribution of severity scores on a 20-point scale of cases
of acute rotavirus gastroenteritis in infants followed prospectively
for about 1 year after vaccination with three doses of rhesus-human
reassortant tetravalent rotavirus vaccine or placebo. A score ‡11 is
generally regarded as indicative of severe rotavirus gastroenteritis.
The line shows point estimates of vaccine efficacy against rotavirus
gastroenteritis from score ‡6 to score ‡15. From ref. [17].
TABLE 1. Characteristics of live oral bovine rotavirus
vaccine strain RIT4237 found in studies in 1982–87
Greater efficacy against severe than mild rotavirus gastroenteritis
Dose response: higher titre ﬁ greater efficacy
Efficacy better than humoral immune response
Uptake enhanced by buffering against stomach acidity
Uptake not (much) compromised by breast feeding
Uptake interfered by oral poliovirus vaccine, particularly first dose of each
No obvious side-effects (diarrhoea or fever)
The findings are largely applicable to currently licensed oral rotavirus vaccines
TABLE 2. Protective efficacy of human rotavirus G1P[8]








Latin America 85 [51]
South Africa 72 [29]
Malawi 49 [29]
The comparison is for two doses of vaccine, 1 year of follow-up, and for severe
rotavirus gastroenteritis.
RVGE, rotavirus gastroenteritis.
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ever, was much greater reactogenicity in comparison with
bovine rotavirus (which was essentially innocuous in
humans): RRV caused a high rate of febrile reactions, coincid-
ing with the peak of viral multiplication about 3–5 days after
administration [14].
Rhesus rotavirus alone did not show impressive protective
efficacy in Finland [15] or the USA [16]. Subsequently RRV
backbone was reassorted with human rotavirus VP7 proteins
representing the G-types G1, G2 and G4 [17]. As RRV rep-
resented G-type 3 (although rhesus) the combination was
called ‘tetravalent’, or RRV-TV vaccine. RRV-TV (later
licensed as RotaShield, Wyeth, Pearl River, NY, USA), given
in three doses, proved to be highly efficacious against severe
RVGE in the USA [18] and in Finland [19], and, was also
quite efficacious in Venezuela [20]. The studies led to the
licensure of RotaShield in the USA in 1998.
The greater efficacy of RRV-TV compared with RRV has
often been attributed to human G-type-specific immunity
[18]. However, this explanation seems, for the most part,
unlikely, because the neutralizing antibody responses to each
of the G-types were generally low whereas the overall
immune response rate after three doses of RRV-TV was
close to 100% [21]. A more plausible explanation would be
that RRV-TV, in contrast to monotypic RRV, will allow for
different G-types to have a chance of ‘taking’ up on each
dosing, with a resulting boost to overall immunity. The high
overall uptake is measured by rotavirus serum IgA, in turn,
antibody to VP6 group antigen using enzyme immunoassay,
and a high level of rotavirus IgA is in good correlation with
protective efficacy [22].
RotaShield was withdrawn in 1999, less than a year after
licensure, because of association with intussusception. Intus-
susception was observed in prelicensure trials, but was not
fully appreciated until about a million doses of the licensed vac-
cine had been given in the USA and about 100 cases had been
seen. Typically, most of the cases of intussusception occurred
3–7 days after dose 1, coinciding with the peak of virus multi-
plication and febrile reactions [23]. The majority of cases of
intussusception occurred when the first dose of RRV-TV was
administered to infants between 3 and 9 months of age as part
of a ‘catch-up’ programme launched in the USA. This age range
is similar to the peak incidence of naturally occurring intussus-
ception. In fact, the risk for intussusception after RotaShield in
infants < 90 days old appeared to be low [24].
Rhesus rotavirus-TV may have a second chance. With an
increasing appreciation of age as a risk factor of intussuscep-
tion, the vaccine has recently been tested in Ghana following
a two-dose schedule of 1–29 days and 30–59 days for the
first and second dose, respectively. Preliminary data suggest
that following such a schedule the vaccine may be both safe
and efficacious in Africa [Armah GE, Kapikian AZ, Vesikari T,
Cunliffe N, Jacobson RM, Burlington BD, Ruiz LP Jr.,
unpublished data].
Human rotavirus G1P[8] vaccine
Human rotavirus G1P[8] vaccine is derived from a clinical
isolate in Cincinnati, grown in cell culture. The first candi-
date vaccine was shown to be efficacious, but still somewhat
reactogenic causing a low rate of fever and some diarrhoea
[25]. After acquisition by GlaxoSmithKline Biologicals
(Rixensart, Belgium), the vaccine strain was cloned (it was
shown to contain two plaque variants) and passaged a fur-
ther 12 times in Rixensart, renamed RIX4414, and eventually,
after licensure, Rotarix.
The rationale of a human rotavirus G1P[8] strain vaccine
was to induce serotype-specific immunity against the most
common human G-type and P-type rotaviruses. As for safety,
it was regarded that a human rotavirus vaccine was unlikely
to cause intussusception, because wild-type human rotavirus
apparently is not associated with intussusception [26]. A tis-
sue-culture-adapted strain RIX4414 is attenuated in compari-
son to wild-type G1 rotavirus in that it has lost its potential
to cause diarrhoea, but, as it retains high infectivity for
humans, it is actually not known whether its potential to
induce intussusception is different from that of wild-type.
In early phase I–II trials in Finnish infants at 2 months of
age the first dose of RIX4414 induced an 88% rotavirus IgA
antibody response, and the second dose increased serocon-
version to 96%. Meanwhile, the geometric mean titre was
not increased. Therefore the second dose does not produce
a booster effect, but, effectively, a successful first dose
induces an immunity that prevents the uptake of the second
dose. This block of the second dose could be attributed to
TABLE 3. Protective efficacy of human-bovine reassortant













The comparison is for three doses of vaccine, 1 year of follow-up, and for
severe rotavirus gastroenteritis.
RVGE, rotavirus gastroenteritis.
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vaccine-induced serotype-specific anti-G1 antibodies. The
immunogenicity of RIX4414 was dependent on the vaccine
titre in the dose range 104–106 [27]. The uptake of RIX4414
in Latin America and South Africa was lower (in this order)
than in Finland, probably because of higher levels of mater-
nally acquired anti-G1 rotavirus antibodies at the time of the
vaccination. To compensate in part for the lower immunoge-
nicity in these parts the final titre of Rotarix vaccine was set
at 105.3 PFU/mL.
RIX4414 vaccine virus was effectively shed in the stools,
demonstrating its multiplication in the intestines. After the first
dose about 60% of the recipients shed the vaccine virus as
detected by enzyme immunoassay, but after the second dose
there was virtually no shedding because in most cases the sec-
ond dose did not ‘take’ [27]. The shedding may be prolonged
in case of immunodeficiencies such as IgA deficiency. Trans-
mission of the vaccine can happen, but is an uncommon event.
As expected from the high uptake, European clinical trials
showed high protective efficacy of Rotarix in the first year
after vaccination, and only slightly less in the second year
[28]. An Asian trial also showed sustained efficacy for
2 years [29]. In contrast, vaccine efficacy in South Africa and
Malawi, as well as in Vietnam and Bangladesh, was
largely restricted to the first year after vaccination [30,31]
(Table 2).
In the European efficacy trial during two rotavirus seasons
several rotavirus types were encountered to draw conclu-
sions on serotype-specific protection of this ‘monovalent’
vaccine. Overall, protection against severe RVGE induced by
Rotarix was similar across rotavirus G-types, whereas there
was some difference in protection against any RVGE with
G1P[8] as the highest (90%) and G2P[4] as the lowest (58%)
[28]. The observation suggests that G1-specific immunity
induced by the homotypic vaccine plays some, albeit only a
minor, role in overall protection.
As most protective efficacy against severe RVGE appears
to be independent of the G- and P-types of Rotarix, the cru-
cial antigen may be VP6, which is the most abundant and
most immunogenic protein of rotavirus and the inducer of
serum IgA antibodies that are used as a correlate of protec-
tion against RVGE. For this reason a monovalent human
rotavirus vaccine can be highly successful in preventing
severe RVGE across serotypes, not only in Europe but also
in Africa [30]. Strain G2P[4] represents a gap in protection.
This strain is not only of different G and P serotype but also
has a VP6 subtype that is slightly different from the other
circulating human rotaviruses. The deficiency in protection is
illustrated by continuous circulation of G2P[4] rotaviruses in




The backbone of bovine-human reassortant pentavalent vac-
cine (RV5, RotaTeq, Merck, Whitehouse Station, NJ, USA)
is the bovine rotavirus strain WC-3, which is a low passage
level isolate of calf rotavirus that was used as a candidate
vaccine in the 1980s [34]. The WC-3 strain bovine rotavirus
was reassorted with VP7 surface proteins of human rotavi-
ruses G1, G2, G3 and G4, and one reassortant was made
between the bovine rotavirus and human VP4 type P[8], for-
merly called P1A. The resulting ‘pentavalent’ vaccine is a mix-
ture of these five reassortants [35].
The original idea of reassortment, as with RRV-TV vac-
cine, was to induce G and P serotype-specific neutralizing
antibody responses to protect against the respective rotavi-
rus types. However, in practice and not unlike with RRV-TV
vaccine, the neutralizing antibody responses to specific sero-
types have been low [36,37], and therefore cannot be
responsible for much of the protective efficacy of this vac-
cine. Rather, multiple serotypes in the vaccine may allow
repeated doses (three altogether) to ‘take’ and build solid
cross-protective immunity, probably based on a high level of
serum IgA antibodies against VP6 group antigen. Hence, the
main advantage of RV5 over monovalent vaccine may be the
possibility of successfully giving three doses and increasing
the level of IgA antibodies. Preliminary efficacy and a dose
finding study of RV5 comparing different vaccine composi-
tions indicated that a monotypic vaccine containing only P[8]
reassortant was inferior to tetravalent and pentavalent com-
positions [38]. This might be because the single reassortant
vaccine did not allow for uptake of repeated doses.
The efficacy of RotaTeq was demonstrated in a large trial
called the Rotavirus Efficacy and Safety Trial (REST), which
was conducted mainly in Europe (largely Finland) and the
USA [36]. The primary end point was efficacy against hospi-
talization or Emergency Department visit due to RVGE.
Against this combined end point, vaccine efficacy was 95%,
and, in an extended follow-up in Finland, the efficacy was
sustained for up to 3.1 years [39]. In a subset that was fol-
lowed more closely, the efficacy was 100% against severe
RVGE and 72% against all RVGE in the first year of follow-up
[39]; in the second year the efficacy against severe RVGE
was sustained at 94% but that against all RVGE decreased to
58% [40].
RotaTeq vaccine protects against severe RVGE associated
with any serotype that has been investigated. Vaccine efficacy
was between 95% against G1 (highest) and 82% against
G2P[4] (lowest) using the combined end point of hospitaliza-
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tions and Emergency Department visits. It is noteworthy that
vaccine efficacy against G9P[8] was also high (94%), even
though this serotype is not included in the vaccine [39].
In Africa, efficacy of RotaTeq has been variable. In a 1-year
follow-up efficacy against severe RVGE was 83% in Kenya,
64% in Ghana and nil in Mali [41]. In the second year vaccine
efficacy was low everywhere. In Vietnam, vaccine efficacy
against severe RVGE was 73% in a 1-year follow-up; in Ban-
gladesh the efficacy was only 43% [31] (Table 3).
Implementation of rotavirus vaccination
In the first 6 years after licensure, universal mass vaccination
against rotavirus has progressed steadily but with consider-
able regional variation.
Rotarix vaccine has been implemented into the national
immunization programmes of 18 countries and territories in
Latin America, as well as in South Africa, Australia and
some European countries including Belgium, Luxembourg,
Austria, Finland and five German Federal States. In Latin
America, the impact has been impressive in Brazil and
Mexico. Brazil was the first country to introduce universal
rotavirus vaccination in March 2006. The estimated field
effectiveness at 85–90% coverage has been 78% [42], and
the annual number of deaths attributable to rotavirus gas-
troenteritis has decreased from 850 to 210 [43]. In Mexico,
the effectiveness has been similar, and the all-cause deaths
including those due to gastroenteritis have been reduced by
41% [44]. The direct evidence of actual prevention of deaths
is extremely important in support of rotavirus vaccination in
areas where mortality from diarrhoea is still high. In Europe,
high effectiveness has been documented in Austria [45] and
Belgium [46].
RotaTeq was introduced in 2006 into a universal vaccina-
tion programme in the USA, and has shown a dramatic
impact on hospitalizations due to RVGE [47,48]. In the USA
it has also been observed that as an indirect vaccine effect,
RV hospitalizations in older children and even adults have
decreased since the implementation of universal mass vacci-
nation of infants [49]. Finland has implemented a universal
immunization programme in 2009 with exclusive use of Ro-
taTeq, and the first results indicate 100% effectiveness
against hospitalization for RVGE for a full three-dose course
(ESPID 2011, abstract [589]).
In Africa, despite lower efficacy of rotavirus vaccines in
general, universal rotavirus vaccination, whether with Ro-
tarix, RotaTeq or other vaccines, would have great potential,
because the number of deaths that could be prevented even
at lower efficacy is substantial. Wider implementation in
Africa (and Asia) is awaiting innovative financial solutions, but
is expected to begin in 2012, with Rwanda and Ghana as
early adopters.
Hurdles of rotavirus vaccination
Rotarix suffered a setback in March 2010 when it was
announced that porcine circovirus 1 (PCV-1) DNA had been
detected in the vaccine. As a result the US Food and Drug
Administration temporarily advised against use of Rotarix in
the USA, and this recommendation was also followed in
some European countries. Meanwhile the European Medi-
cines Agency and WHO continued to recommend use of
Rotarix. Although PCV-1 is not known to infect humans, let
alone cause disease, its presence in the vaccine is clearly
undesirable. As PCV-1 infection was discovered in the mas-
ter seed virus it has been necessary to revise all steps in the
production process of Rotarix, but PCV-1-free vaccine will
become available soon. PCV-1 and PCV-2 DNA fragments
were also discovered in RotaTeq in 2010, but this contami-
nation was traced to batches of trypsin used in the produc-
tion process and has been eliminated.
Both Rotarix and RotaTeq have been recently associated
with a low incidence of vaccine attributable intussusception, of
the order of 1:51 000 to 1:68 000 in the 7 days after Dose 1
for both vaccines [43]. This is much less than the vaccine-
attributable risk of RotaShield, but does not take into account
the fact that most cases of intussusception following Rota-
Shield occurred in infants aged over 90 days in the so-called
catch-up programme [24]. In the prelicensure studies of
Rotarix and RotaTeq this age was strictly avoided. It is also
noteworthy that the US postmarketing surveillance has not
identified increased risk of intussusception for RotaTeq [50]
and in the USA the age limit for the first dose of rotavirus vac-
cine (75% RotaTeq, 25% Rotarix) is well adhered to. In Europe
the recommendation for Rotarix has been to give two doses
at an interval of 4 weeks between ages 6 and 24 weeks. This
allows, in theory, administration of the first dose up to
20 weeks of age, which is later than in prelicensure studies.
Although most cases in Mexico have occurred in infants youn-
ger than this, it is not clear what the role of age is in intussus-
ception associated with Rotarix or with RotaTeq elsewhere.
Despite recent safety issues it is likely that the progress of
rotavirus vaccination, using live oral vaccines, will continue.
GAVI support will help to introduce rotavirus vaccination in
Africa and many Asian countries. New vaccines, produced in
India or China, will possibly contribute to more widespread
use of rotavirus vaccine in these countries. The balance
between the benefits (prevention of mortality) and risks
CMI Vesikari Rotavirus vaccination 61
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(very rare intussusception) is overwhelmingly on the side of
continuous and expanding public-health use of oral rotavirus
vaccines.
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